![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- Crosignani PG, Vercellini P, Mosconi P, Oldani S, Cortesi I, De Giorgi O. 1997. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in treatment of dysfunctional uterine bleeding. Obstetrics and Gynecology 90:257–263.
- Jones RL, Critchley HO. 2000. Morphological and functional changes in human endometrium following intrauterine levonor-gestrel delivery. Human Reproduction 15\(suppl 3):162— 172.
- Jensen JT. 2002. Noncontraceptive applications of the levonorges-trel intrauterine system. Current Women's Health Reports 2:417— 422.
- Rutanen EM, Salmi A, Nyman T. 1997. mRNA expression of insulin like growth factor-I (IGF-I) is suppressed and those of IGF-II and IGF-binding protein-1 are constantly expressed in the endometrium during use of an intrauterine levonorgestrel system. Molecular Human Reproduction 3:749–754.